[1] Shapiro YN, O'Donnell EK. Oncologist perspective:role of imaging in myeloma[J]. Skeletal Radiol, 2022,51(1): 123-133.
[2] Palmer WE, Simeone FJ.Can dual-energy CT challenge MR imaging in the diagnosis of focal infiltrative bone marrow lesions?[J]. Radiology, 2018, 286(1): 214-216.
[3] Derlin T, Bannas P.Imaging of multiple myeloma: Current concepts[J]. World J Orthop, 2014, 5(3): 272-282.
[4] Li SD, Wang YF, Qi JY, et al.Clinical Features of Bone Complications and Prognostic Value of Bone Lesions Detected by X-ray Skeletal Survey in Previously Untreated Patients with Multiple Myeloma[J]. Indian J Hematol Blood Transfus, 2010, 26(3): 83-88.
[5] 印惠,赵卫东,刘强,等. 多发性骨髓瘤全身低剂量CT的研究进展[J]. 中国中西医结合影像学杂志,2017,15(5):620-622.
[6] Koutoulidis V, Terpos E, Klapa I, et al.Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation[J]. AJR Am J Roentgenol, 2021, 216(3): 742-751.
[7] Kosmala A,Weng AM,Heidemeier A,et al.Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis[J]. Radiology, 2018, 286(1): 205-213.
[8] Thomas C, Schabel C, Krauss B, et al.Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma[J]. AJR Am J Roentgenol, 2015,204(3): W324-331.
[9] Werner S, Krauss B, Horger M, et al.Dual-Energy CT-Based Bone Marrow Imaging in Multiple Myeloma: Assessment of Focal Lesions in Relation to Disease Status and MRI Findings[J]. Acad Radiol, 2022, 29(2): 245-254.
[10] Portet M, Owens E, Howlett D, et al.The use of whole-body MRI in multiple myeloma[J]. Clin Med (Lond), 2019, 19(4): 355-356.
[11] Wang T, Peng X, Qiao W, et al.The role of CT in PET/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system[J]. Mol Clin Oncol, 2020, 13(1): 13-18.
[12] Messiou C, Giles S, Collins DJ, et al.Assessing response of myeloma bone disease with diffusion-weighted MRI[J]. Br J Radiol, 2012, 85(1020): e1198-1203.
[13] Koutoulidis V, Papanikolaou N, Moulopoulos LA.Functional and molecular MRI of the bone marrow in multiple myeloma[J]. Br J Radiol, 2018, 91(1088): 20170389.
[14] Lai AYT, Riddell A, Barwick T, et al.Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma[J]. Eur Radiol, 2020, 30(1): 320-327.
[15] Zhang L, Wang Q, Wu X, et al.Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma[J]. Eur Radiol, 2021, 31(4): 1843-1852.
[16] Park HY, Kim KW, Yoon MA, et al.Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response[J]. Cancer Imaging, 2020, 20(1): 14.
[17] Mesguich C, Hindie E, deSenneville BD, et al. Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis[J]. Nucl Med Commun, 2021, 42(10): 1135-1143.
[18] Takahashi MES, Mosci C, Souza EM, et al.Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma[J]. Sci Rep, 2019, 9(1): 16429.
[19] Zhou X, Dierks A, Kertels O, et al.The Link between Cytogenetics/Genomics and Imaging Patternsof Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT[J]. Cancers(Basel), 2020, 12(9): 2399.
[20] Bailly C, Carlier T, Jamet B,et al.Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study[J]. Clin Cancer Res,2018, 24(21): 5219-5224. |
